This trial is evaluating whether Bimekizumab will improve 2 primary outcomes and 28 secondary outcomes in patients with Psoriatic Arthritis. Measurement will happen over the course of From PA0012 Entry Visit until Safety Follow-Up (up to Week 212).
This trial requires 1131 total participants across 1 different treatment group
This trial involves a single treatment. Bimekizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
"The signs of arthritis are joint inflammation, joint swelling, and stiffness. These may be present without joint trauma, or when there is joint trauma. On palpation, arthritic joints may appear red, warm and tender. Involvement of the metacarpophalangeal and metatarsophalangeal joints is commonly found. Other symptoms may include swelling in the wrists and legs, joint stiffness, pain when moving the joints, warmth, and redness. Pain is also a common symptom of inflammatory arthritis." - Anonymous Online Contributor
"In people with arthritis and no psoriasis, the risk of developing psoriasis is about the same as for the general population. Psoriasis starts before the arthritis. The arthritis-psoriasis link is probably due to the presence of a shared susceptibility gene." - Anonymous Online Contributor
"The most common treatment for arthritis is nonpharmaceutical. Drugs such as nonsteroidal anti-inflammatory drugs (NSAIDs) may be used in the short-term. There is no strong evidence supporting that one treatment (anti-TNF or other) is better than the other. There are no conclusive reviews that have been done to compare their effectiveness. However, there is concern that there are adverse effects related to medications and that people on these medications should be encouraged to report any side effects to their doctors as often as they need to. Painkillers such as opioids are rarely used. There is no clear evidence on which anti-oxidants, such as vitamin C or vitamin E, may be useful in treating joint pain." - Anonymous Online Contributor
"Despite the evidence showing in favour of remission for PsA with biological therapy (i.e. TNF-blocker (i.e. infliximab (infusion, Humira)) and the first anti-TNF in combination with methotrexate (MTX)) versus placebo, no remission has been found for PsA. Moreover, a high remission rate for PsA with methotrexate and IFN-alpha therapy has been demonstrated." - Anonymous Online Contributor
"Psoriatic arthritis, although rare, is an independent cause of chronic, debilitating pain in the wrists, ankles, or knees. Infiltration of the synovium by T lymphocytes and abnormal bone erosions (osteolysis) are important features. It can occur with or without arthritis or psoriasis." - Anonymous Online Contributor
"Although more than 50 million Americans suffer from at least one arthritis, over 45 million of them have arthritis that keeps them out of work for one month or longer." - Anonymous Online Contributor
"Onset of improvement in joint symptoms occurred within the first 8 weeks of commencement of treatment with bimekizumab. The majority of patients (81%) on treatment at any time point had a decrease in pain and inflammation of at least 1 point on the DAS28-ESR. Overall, 24% of patients were on treatment by week 8." - Anonymous Online Contributor
"There are numerous reports of bimekizumab's efficacy both as monotherapy and in combination with many immunomodulatory agents including etanercept, adalimumab, or infliximab. Further studies are warranted to see whether it achieves similar results in the context of psoriasis treatment." - Anonymous Online Contributor
"In a representative sample of persons with arthritis, psoriatic, and rheumatoid arthritis, the average ages of onset of disease are at least 6 to 12 years older than for similar conditions in the general population." - Anonymous Online Contributor
"Both trials showed benefit when bimekizumab was used as a monotherapy. Both trials did not show benefit in patients receiving bimekizumab when paired with methotrexate. Further studies with more patients are needed to assess its utility in the long term as compared to other treatments." - Anonymous Online Contributor
"Treatment with BTZ does not reduce pain at 2-week or 3-month assessments. However, patients in the BTZ group reported significantly fewer joint flares compared with placebo, at 3-week and 3-month assessments." - Anonymous Online Contributor
"There were no detectable differences in serious events or in patients who could be treated safely with bimekizumab in this retrospective analysis. As there was a tendency towards a more frequent use of steroids, especially in the first year, randomized controlled studies must be performed to investigate the long-term effects of bimekizumab in psoriasis." - Anonymous Online Contributor